The mechanism. In September 2024 the DOJ sued Visa for allegedly monopolizing debit-card processing — locking merchants into its network via penalty pricing and paying would-be competitors like Apple and PayPal to stay out of the market. That case is now in active discovery (fact discovery runs through October 2026), and Mastercard sits under parallel scrutiny for its own network rules. The Federal Reserve is simultaneously revisiting Regulation II, the Durbin Amendment rule that caps debit interchange — with a federal court having vacated the existing fee standard in 2025, forcing a rewrite. Read together, the signal to merchants and issuers is the same: routing exclusivity and network-set interchange are legally fragile. That doesn't kill Visa or Mastercard, but it strengthens the hand of anyone who already owns an alternative rail — and the biggest owners of alternative rails in consumer payments are the large banks that issue co-brand and proprietary credit cards, where interchange is set by contract with a retailer, not dictated by a duopoly network under a DOJ microscope.
Antitrust Action Against Visa and Mastercard: Why JPM and BAC Are the Quiet Winners
DOJ scrutiny of card-network routing and interchange rules is filed under "network risk" — but it actually pushes merchants and issuers toward bank-owned payment rails and co-brand economics that JPMorgan and Bank of America already control.
The DOJ's antitrust case gets filed under "network risk" — but every rule that weakens Visa and Mastercard's grip on routing is a rule that makes JPMorgan's and Bank of America's own card economics more valuable.
Who cashes in:
- JPM — JPMorgan is the largest U.S. card issuer by outstandings and holds premier co-brand partnerships (Amazon, Southwest, United, Marriott) where JPM negotiates economics directly with the merchant partner, largely insulated from network-routing antitrust noise. As card networks face rule changes, JPM's ability to bundle lending, rewards funding, and merchant-acquiring services (via its Chase Payment Solutions/WePay stack) makes it a natural home for large retailers looking to bring more of the transaction in-house.
- BAC — Bank of America runs one of the largest small-business and consumer card portfolios and its own merchant-services arm (historically via the Bank of America Merchant Services joint venture lineage), giving it a direct hand in acquiring economics rather than pure network dependency. A weaker, more contestable Visa/Mastercard routing regime increases BAC's leverage to negotiate preferred processing and co-brand terms with retail partners.
- SCHW — Charles Schwab, as a growing deposit-and-card platform through its bank subsidiary, benefits at the margin from any structural shift that makes bank-issued card products more valuable relative to pure network tolls, though this is a smaller, indirect tailwind versus JPM and BAC.
Who is exposed:
Visa and Mastercard themselves are not in the investable universe here, but the read-through losers are companies most dependent on undisturbed network-set interchange and routing exclusivity — payment processors and merchant acquirers whose margins are a spread on network fees that regulators are actively trying to compress. Any durable Fed rewrite of Regulation II that lowers the debit interchange cap also mechanically shrinks issuer-side debit revenue across the board, a modest offsetting headwind even for JPM and BAC's debit books, though credit and co-brand economics (the bigger profit pool) sit outside Reg II's debit-only scope.
The play. This is a slow-moving structural story, not a headline trade — discovery in DOJ v. Visa runs into late 2026 and any Fed interchange rule will take quarters to finalize. Watch for: (1) new or expanded co-brand deal announcements from JPM or BAC, (2) the Fed's re-proposed Regulation II interchange cap, expected as a formal Federal Register rule, and (3) merchant-side commentary in DOJ v. Visa discovery filings about alternative routing preferences. None of this is a reason to buy or sell anything — it's a mechanism to watch, not a signal to act on.
Source: original report ↗
Free: catalyst alerts, straight to your inbox.
Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $40/moJoin the owners who run ahead of the industry. Cancel anytime, one click.